Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic

Vasa. 2019 Mar;48(2):109-111. doi: 10.1024/0301-1526/a000778.
No abstract available

MeSH terms

  • Angioplasty, Balloon*
  • Arterial Occlusive Diseases* / drug therapy
  • Femoral Artery
  • Humans
  • Paclitaxel / therapeutic use*
  • Popliteal Artery
  • Treatment Outcome
  • Vascular Patency

Substances

  • Paclitaxel